These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
682 related articles for article (PubMed ID: 8331552)
21. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909 [TBL] [Abstract][Full Text] [Related]
22. Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. Wong YN; Wong PC J Pharm Pharmacol; 1996 May; 48(5):492-7. PubMed ID: 8799873 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. Mochizuki S; Sato T; Furuta K; Hase K; Ohkura Y; Fukai C; Kosakai K; Wakabayashi S; Tomiyama A J Cardiovasc Pharmacol; 1995 Jan; 25(1):22-9. PubMed ID: 7723348 [TBL] [Abstract][Full Text] [Related]
24. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193 [TBL] [Abstract][Full Text] [Related]
25. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Mizuno M; Sada T; Ikeda M; Fukuda N; Miyamoto M; Yanagisawa H; Koike H Eur J Pharmacol; 1995 Oct; 285(2):181-8. PubMed ID: 8566137 [TBL] [Abstract][Full Text] [Related]
26. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. Chang RS; Siegl PK; Clineschmidt BV; Mantlo NB; Chakravarty PK; Greenlee WJ; Patchett AA; Lotti VJ J Pharmacol Exp Ther; 1992 Jul; 262(1):133-8. PubMed ID: 1625192 [TBL] [Abstract][Full Text] [Related]
27. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. Wong PC; Timmermans PB J Pharmacol Exp Ther; 1991 Jul; 258(1):49-57. PubMed ID: 2072311 [TBL] [Abstract][Full Text] [Related]
28. In vitro pharmacology of DuP 753. Chiu AT; McCall DE; Price WA; Wong PC; Carini DJ; Duncia JV; Wexler RR; Yoo SE; Johnson AL; Timmermans PB Am J Hypertens; 1991 Apr; 4(4 Pt 2):282S-287S. PubMed ID: 1854453 [TBL] [Abstract][Full Text] [Related]
29. In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. Olins GM; Corpus VM; McMahon EG; Palomo MA; Schuh JR; Blehm DJ; Huang HC; Reitz DB; Manning RE; Blaine EH J Pharmacol Exp Ther; 1992 Jun; 261(3):1037-43. PubMed ID: 1602371 [TBL] [Abstract][Full Text] [Related]
30. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Cazes M; Provost D; Versigny A; Cloarec A Eur J Pharmacol; 1995 Sep; 284(1-2):157-70. PubMed ID: 8549620 [TBL] [Abstract][Full Text] [Related]
31. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. Kubo K; Kohara Y; Yoshimura Y; Inada Y; Shibouta Y; Furukawa Y; Kato T; Nishikawa K; Naka T J Med Chem; 1993 Aug; 36(16):2343-9. PubMed ID: 8360879 [TBL] [Abstract][Full Text] [Related]
32. Dihydropyrimidine angiotensin II receptor antagonists. Atwal KS; Ahmed SZ; Bird JE; Delaney CL; Dickinson KE; Ferrara FN; Hedberg A; Miller AV; Moreland S; O'Reilly BC J Med Chem; 1992 Dec; 35(25):4751-63. PubMed ID: 1469703 [TBL] [Abstract][Full Text] [Related]
33. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Hara M; Kiyama R; Nakajima S; Kawabata T; Kawakami M; Ohtani K; Itazaki K; Fujishita T; Fujimoto M Eur J Pharmacol; 1995 Apr; 289(2):267-73. PubMed ID: 7621900 [TBL] [Abstract][Full Text] [Related]
34. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. Kawamura M; Terashita Z; Okuda H; Imura Y; Shino A; Nakao M; Nishikawa K J Pharmacol Exp Ther; 1993 Sep; 266(3):1664-9. PubMed ID: 8371164 [TBL] [Abstract][Full Text] [Related]
35. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist. Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700 [TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation. Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological profile of TH-142177, a novel orally active AT1-receptor antagonist. Nozawa Y; Haruno A; Oda N; Yamasaki Y; Matsuura N; Miyake H; Yamada S; Kimura R Fundam Clin Pharmacol; 1997; 11(5):395-401. PubMed ID: 9342592 [TBL] [Abstract][Full Text] [Related]
38. DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists. Chiu AT; Carini DJ; Duncia JV; Leung KH; McCall DE; Price WA; Wong PC; Smith RD; Wexler RR; Timmermans PB Biochem Biophys Res Commun; 1991 May; 177(1):209-17. PubMed ID: 2043107 [TBL] [Abstract][Full Text] [Related]
39. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100 [TBL] [Abstract][Full Text] [Related]
40. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177. Okunishi H; Song K; Oka Y; Kobayashi T; Kawamoto T; Ishihara H; Mori N; Miyazaki M Jpn J Pharmacol; 1993 Jul; 62(3):239-44. PubMed ID: 8411773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]